Granted Patent
B2
US 12,605,344 · App. 18/083,458 · Granted Apr 21, 2026
Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
Assignee:
The Trustees of Princeton University
A61K9/5138A61K9/5146A61K9/5192A61K31/00A61K31/405A61K31/7036A61K38/063A61K38/14A61K38/47C09B67/0097C12Y302/01017
View Patent ↗
Loading inventors, assignments & file history…
Abstract
An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.
Claims (30)
1 . A nanoparticle comprising:
a core comprising a more polar region of a linear copolymer and a water-soluble agent,
a shell comprising a less polar region of the linear copolymer, and
a coating,
wherein the more polar region of the linear copolymer comprises a peptide,
wherein the coating comprises an inner region and an outer region,
wherein the inner region comprises a hydrophobic region of an amphiphilic polymer, and
wherein the outer region comprises a hydrophilic region of the amphiphilic polymer.
2 . The nanoparticle of claim 1 , wherein the linear copolymer is a diblock copolymer.
3 . The nanoparticle of claim 1 , wherein the linear copolymer consists of a hydrophilic block coupled with a hydrophobic block.
4 . The nanoparticle of claim 1 , wherein the more polar region of the linear copolymer comprises an anionic more polar region.
5 . The nanoparticle of claim 1 , wherein the more polar region comprises poly(glutamic acid), poly(aspartic acid), or a combination.
6 . The nanoparticle of claim 1 , wherein the more polar region of the linear copolymer comprises a cationic more polar region.
7 . The nanoparticle of claim 1 , wherein the more polar region comprises polylysine, polyarginine, or a combination.
8 . The nanoparticle of claim 1 , wherein the more polar region is a poly(amino acid).
9 . The nanoparticle of claim 1 , wherein the more polar region is a polypeptide.
10 . The nanoparticle of claim 1 , wherein the linear copolymer is biodegradable.
11 . The nanoparticle of claim 1 , wherein the less polar region comprises poly(lactic acid) (PLA), poly(glycolic acid), poly(lactic-co-glycolic acid) (PLGA), poly(caprolactone) (PCL), or a combination.
12 . The nanoparticle of claim 1 ,
wherein the copolymer is a block copolymer,
wherein the more polar region of the copolymer consists of poly(glutamic acid) and/or poly(aspartic acid), and
wherein the less polar region of the copolymer consists of poly(lactic acid) (PLA) or poly(lactic-co-glycolic acid) (PLGA).
13 . The nanoparticle of claim 1 , wherein the nanoparticle has an average size of at least 50 nm and at most 200 nm.
14 . The nanoparticle of claim 1 , wherein the more polar region of the copolymer in the core is crosslinked.
15 . The nanoparticle of claim 1 , wherein the water-soluble agent is selected from the group consisting of a biologic material, an amino acid, a peptide, a protein, DNA, RNA, a saccharide, glutathione, tryptophan, a lysozyme, glucagonlike peptide-I (GLP-1), a water-soluble small molecule therapeutic, tobramycin, vancomycin, an imaging agent, eosin, eosin Y, tartrazine, a metal chelate, a gadolinium chelate, and gadolinium diethylene triamine pentaacetic acid (GD-DTPA).
16 . The nanoparticle of claim 1 , wherein the amphiphilic polymer of the coating is selected from the group consisting of a block copolymer, a diblock copolymer, a triblock copolymer, and a multiblock copolymer.
17 . The nanoparticle of claim 1 , wherein the amphiphilic polymer of the coating is selected from the group consisting of poly(lactic acid)-block-poly(ethylene glycol) (PLA-b-PEG), poly(lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG), and poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide) (PEO-b-PPO-b-PEO).
18 . The nanoparticle of claim 1 , wherein the amphiphilic polymer of the coating is a polyethylene glycol-lipid (PEG-lipid).
19 . The nanoparticle of claim 1 , wherein the less polar region of the linear copolymer comprises poly(n-butyl acrylate) (PBA).
20 . A method of treating a cancer or AIDS, comprising administering the nanoparticle of claim 1 to a patient suffering from the cancer or the AIDS, wherein the water-soluble agent is capable of treating the cancer or the AIDS.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 17, 2022
From: PAGELS, ROBERT F.; PRUD'HOMME, ROBERT K.
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 062151/0759 →
Continuity (4)
Division
15321588
Provisional Application
62016363
· Jun 24, 2014
References Cited (360)
US 1690760A
· Volwiler
· 1928
[cited by applicant]
US 4342653A
· Halverson
· 1982
[cited by applicant]
US 4382982A
· Whillans
· 1983
[cited by applicant]
US 4678516A
· Alderman et al.
· 1987
[cited by applicant]
US 4695464A
· Alderman
· 1987
[cited by applicant]
US 4888238A
· Katz et al.
· 1989
[cited by applicant]
US 4999417A
· Domb
· 1991
[cited by applicant]
US 5366734A
· Hutchinson
· 1994
[cited by applicant]
US 5578325A
· Domb et al.
· 1996
[cited by applicant]
US 5851579A
· Wu et al.
· 1998
[cited by applicant]
US 6291013B1
· Gibson et al.
· 2001
[cited by applicant]
US 6383500B1
· Wooley et al.
· 2002
[cited by applicant]
US 6610653B1
· Backstrom et al.
· 2003
[cited by applicant]
US 6730322B1
· Bernstein et al.
· 2004
[cited by applicant]
US 6998426B2
· L'Alloret
· 2006
[cited by applicant]
US 7052719B2
· Bernstein
· 2006
[cited by applicant]
US 7842308B2
· McAllister et al.
· 2010
[cited by applicant]
US 7977024B2
· Zhou et al.
· 2011
[cited by applicant]
US 8137699B2
· Johnson et al.
· 2012
[cited by applicant]
US 8288001B1
· Fan et al.
· 2012
[cited by applicant]
US 8298581B2
· Fischer et al.
· 2012
[cited by applicant]
US 8603514B2
· Yang
· 2013
[cited by applicant]
US 8623329B1
· Hansen et al.
· 2014
[cited by applicant]
US 8703196B2
· Babcock et al.
· 2014
[cited by applicant]
US 9504658B2
· Miller et al.
· 2016
[cited by applicant]
US 9603830B2
· Powell et al.
· 2017
[cited by applicant]
US 9782358B2
· Kataoka et al.
· 2017
[cited by applicant]
US 20040052824A1
· Chacra-Vernet
· 2004
[cited by applicant]
US 20050228074A1
· Warren et al.
· 2005
[cited by applicant]
US 20060057215A1
· Raiche et al.
· 2006
[cited by applicant]
US 20060078624A1
· Zalipsky et al.
· 2006
[cited by applicant]
US 20060224095A1
· Claverie et al.
· 2006
[cited by applicant]
US 20070042498A1
· Ebner
· 2007
[cited by applicant]
US 20070231355A1
· Quadir et al.
· 2007
[cited by applicant]
US 20080145432A1
· Kakizawa et al.
· 2008
[cited by applicant]
US 20080160305A1
· Warren et al.
· 2008
[cited by applicant]
US 20090061009A1
· Schwarz et al.
· 2009
[cited by applicant]
US 20090068743A1
· Turnell et al.
· 2009
[cited by applicant]
US 20100150994A1
· Kotyla
· 2010
[cited by applicant]
US 20100166866A1
· Fischer et al.
· 2010
[cited by applicant]
US 20100305219A1
· Granick et al.
· 2010
[cited by applicant]
US 20110022129A1
· Prud'homme et al.
· 2011
[cited by applicant]
US 20110064821A1
· Catchpole et al.
· 2011
[cited by applicant]
US 20110200828A1
· Li et al.
· 2011
[cited by applicant]
US 20110206739A1
· Nicolosi et al.
· 2011
[cited by applicant]
US 20110229516A1
· Ochomogo et al.
· 2011
[cited by applicant]
US 20110293701A1
· Bratzler et al.
· 2011
[cited by applicant]
US 20120121510A1
· Brem et al.
· 2012
[cited by applicant]
US 20120230913A1
· Johnston et al.
· 2012
[cited by applicant]
US 20130064954A1
· Ochomogo et al.
· 2013
[cited by applicant]
US 20130171208A1
· Smith et al.
· 2013
[cited by applicant]
US 20130337078A1
· Mayer et al.
· 2013
[cited by applicant]
US 20140037573A1
· Eliasof et al.
· 2014
[cited by applicant]
US 20140099379A1
· Beck-Broichsitter et al.
· 2014
[cited by applicant]
US 20150086618A1
· Onyuksel et al.
· 2015
[cited by applicant]
US 20150218198A1
· Petermann et al.
· 2015
[cited by applicant]
US 20150290233A1
· Yarden et al.
· 2015
[cited by applicant]
US 20160235677A1
· Hoerr et al.
· 2016
[cited by applicant]
US 20160346266A1
· Tolleth et al.
· 2016
[cited by applicant]
US 20170042823A1
· Prud'Homme et al.
· 2017
[cited by applicant]
US 20170151339A1
· White et al.
· 2017
[cited by applicant]
US 20190192444A1
· Barzilay et al.
· 2019
[cited by applicant]
US 20200147032A1
· Prud'homme et al.
· 2020
[cited by applicant]
CN 100389766C
· 2008
[cited by applicant]
CN 102334609A
· 2012
[cited by applicant]
CN 104042567A
· 2014
[cited by applicant]
CN 105213250A
· 2016
[cited by applicant]
CN 106750272A
· 2017
[cited by applicant]
EP 2962752A1
· 2016
[cited by applicant]
JP 2000514791A
· 2000
[cited by applicant]
JP 2003513019A
· 2003
[cited by applicant]
JP 2008297288A
· 2008
[cited by examiner]
JP 2011506499A
· 2011
[cited by applicant]
JP 2014514275A
· 2014
[cited by applicant]
JP 2014516045
· 2014
[cited by applicant]
JP 2015129128A
· 2015
[cited by applicant]
JP 2015529683A
· 2015
[cited by applicant]
JP 2017505800A
· 2017
[cited by applicant]
JP 2018535228A
· 2018
[cited by applicant]
WO 1994008599A1
· 1994
[cited by applicant]
WO 1997049736A2
· 1997
[cited by applicant]
WO WO1997049387A1
· 1997
[cited by applicant]
WO 2001022937A1
· 2001
[cited by applicant]
WO 2002076441A1
· 2002
[cited by applicant]
WO 2002078674A1
· 2002
[cited by applicant]
WO WO2002092069A1
· 2002
[cited by applicant]
WO 2009080164A1
· 2009
[cited by applicant]
WO WO2010148653A1
· 2010
[cited by examiner]
WO 2012122544A2
· 2012
[cited by applicant]
WO 2012160088
· 2012
[cited by applicant]
WO WO2013023003A1
· 2013
[cited by examiner]
WO 2013160773A2
· 2013
[cited by applicant]
WO 2014043625A1
· 2014
[cited by applicant]
WO 2014133172A1
· 2014
[cited by applicant]
WO 2014165679A1
· 2014
[cited by applicant]
WO 2015123562A1
· 2015
[cited by applicant]
WO 2015130835A1
· 2015
[cited by applicant]
WO 2015200054A2
· 2015
[cited by applicant]
WO 2015200054A9
· 2015
[cited by applicant]
WO 2016193810A1
· 2016
[cited by applicant]
WO 2017089942A1
· 2017
[cited by applicant]
WO 2017112828A1
· 2017
[cited by applicant]
WO WO2017130046A1
· 2017
[cited by applicant]
WO 2019055539A1
· 2019
[cited by applicant]
WO WO2019050969A1
· 2019
[cited by applicant]
WO 2019090030A1
· 2019
[cited by applicant]
WO 2020018890A1
· 2020
[cited by applicant]
WO WO2020227350A1
· 2020
[cited by applicant]
WO WO2020252346A1
· 2020
[cited by applicant]
WO WO2021046078A1
· 2021
[cited by applicant]
Bin Xu, Hongjing Dou, Ke Tao, Kang Sun, Rong Lu, and Weibin Shi. “Influence of experimental parameters and the copolymer structure on the size control of nanospheres in double emulsion method.” Journal of Polymer Resear…
[cited by examiner]
English Translation of JP 2008297288 A. Obtained from https://patents.google.com/patent/JP2008297288A/en?oq=JP+2008297288+ on Feb. 13, 2025, originally published 2008, 8 printed pages. (Year: 2008).
[cited by examiner]
Kai Qi, Qinggao Ma, Edward E. Remsen, Christopher G. Clark, Jr., and Karen L. Wooley. “Determination of the Bioavailability of Biotin Conjugated onto Shell Cross-Linked (SCK) Nanoparticles.” Journal of the American Chem…
[cited by examiner]
Naomi Kohen. “Characterization of Polystyrene-block-poly(acrylic acid) Micelles.” Thesis, Massachusetts Institute of Technology, Jun. 2005, pp. 1-38. (Year: 2005).
[cited by examiner]
Olivier Colombani et al. “Structure of Micelles of Poly(n-butyl acrylate)-block-poly(acrylic acid) Diblock Copolymers in Aqueous Solution.” Macromolecules, vol. 40, 2007, pp. 4351-4362. (Year: 2007).
[cited by examiner]
Olivier Colombani et al. “Synthesis of Poly(n-butyl acrylate)-block-poly(acrylic acid) Diblock Copolymers by ATRP and Their Micellization in Water.” Macromolecules, vol. 40, 2007, pp. 4338-4350. (Year: 2007).
[cited by examiner]
Elham Eghbali et al. “Rheology and Phase Behavior of Poly(n-butyl acrylate)-block-poly(acrylic acid) in Aqueous Solution.” Langmuir, vol. 22, 2006, pp. 4766-4776. (Year: 2006).
[cited by examiner]
Byeong-Su Kim and T. Andrew Taton. “Multicomponent Nanoparticles via Self-Assembly with Cross-Linked Block Copolymer Surfactants.” Langmuir, vol. 23, 2007, pp. 2198-2202. (Year: 2007).
[cited by examiner]
Marina Talelli, Matthias Barz, Christianne J.F. Rijcken, Fabian Kiessling, Wim E. Hennink, and Twan Lammers. “Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translatio…
[cited by examiner]
U.S. Appl. No. 16/517,510 Notice of Allowance and Notice of Allowability dated Nov. 23, 2022.
[cited by applicant]
U.S. Appl. No. 16/816,241 Notice of Allowance and Notice of Allowability dated Nov. 16, 2022.
[cited by applicant]
Erre et al. “Chromium(III) Acetate, Chromium(III) Acetate Hydroxide, or mu3-Oxo-esakis-(mu2-acetato-O,O′)-triaqua-trichromium(III) Acetate?”, Journal of Chemical Education, (Apr. 1997) vol. 74, No. 4, pp. 432-435.
[cited by applicant]
Liang et al., “Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells”, Journal of Controlled Release, (2005) vol. 105, pp. 213-22…
[cited by applicant]
Talleli et al., “Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation”, Nano Today (2015) vol. 10, pp. 93-117.
[cited by applicant]
U.S. Appl. No. 16/253,850 U.S. Patent & Trademark Office (USPTO) Office Action of Sep. 23, 2021, 23 pages.
[cited by applicant]
U.S. Appl. No. 16/253,850 U.S. Patent & Trademark Office (USPTO) Office Action of Sep. 8, 2020, 23 pages.
[cited by applicant]
U.S. Appl. No. 16/253,850 U.S. Patent & Trademark Office (USPTO) Supplemental Notice of Allowability of Dec. 19, 2022, 2 pages.
[cited by applicant]
U.S. Appl. No. 16/253,850 U.S. Patent & Trademark Office (USPTO) Notice of Allowance & Notice of Allowability of Sep. 13, 2022, 22 pages.
[cited by applicant]
U.S. Appl. No. 16/253,850 U.S. Patent & Trademark Office (USPTO) Notice of Allowance & Notice of Allowability of Apr. 12, 2022, 24 pages.
[cited by applicant]
U.S. Appl. No. 16/253,850 U.S. Patent & Trademark Office (USPTO) Aug. 11, 2021 dated Summary of Interview of Aug. 9, 2021, 3 pages.
[cited by applicant]
U.S. Appl. No. 16/253,850 U.S. Patent & Trademark Office (USPTO) Restriction Requirement of Apr. 7, 2020.
[cited by applicant]
International Preliminary Report on Patentability mailed Mar. 26, 2020 (issued Mar. 17, 2020) in International Application No. PCT/US2018/050714.
[cited by applicant]
U.S. Patent & Trademark Office (USPTO) Office Action dated Sep. 23, 2021 for U.S. Appl. No. 16/253,850.
[cited by applicant]
U.S. Appl. No. 16/761,140 Office Action dated Aug. 26, 2022.
[cited by applicant]
Rádler et al., “Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes,” Science, vol. 275, No. 5301, pp. 810-814 (1997).
[cited by applicant]
Salentinig et al., “Self-Assembled Structures and pKa Value of Oleic Acid in Systems of Biological Relevance” Langmuir, vol. 26, No. 14, pp. 11670-11679 (2010).
[cited by applicant]
Schwendeman et al., “Injectable controlled release depots for large molecules”, Journal of Controlled Release, vol. 190, pp. 240-253 (2014).
[cited by applicant]
Serajuddin, “Salt formation to improve drug solubility” Advanced Drug Delivery Reviews, vol. 59, No. 7, pp. 603-616 (2007).
[cited by applicant]
Shah et al., Poly (glycolic acid-co-DL-lactic acid): diffusion or degradation controlled drug delivery?, Journal of Controlled Release, vol. 18, pp. 261-270 (1992).
[cited by applicant]
Sohn et al., “Polymer prodrug approaches applied to paclitaxel,” Polymer Chemistry, vol. 1, No. 6, pp. 778-792 (2010).
[cited by applicant]
Song et al., “A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system,” Journal of Controlled Release, vol. 229, pp. 106-119 (2016).
[cited by applicant]
Turro et al., “Spectroscopic probe analysis of protein-surfactant interactions: the BSA/SDS system,” Langmuir, vol. 11, No. 7, pp. 2525-2533 (1995).
[cited by applicant]
U.S. Appl. No. 16/517,510 Notice of Allowance May 9, 2022.
[cited by applicant]
U.S. Appl. No. 16/517,510 Restriction Requirement Mar. 19, 2021.
[cited by applicant]
U.S. Appl. No. 16/517,510 Office Action mailed Sep. 24, 2021.
[cited by applicant]
U.S. Appl. No. 16/761,140 Office Action Feb. 8, 2022.
[cited by applicant]
U.S. Appl. No. 16/761,140 Restriction Requirement of Aug. 19, 2021.
[cited by applicant]
U.S. Appl. No. 16/816,241 Office Action May 12, 2022.
[cited by applicant]
U.S. Appl. No. 16/816,241 Restriction Requirement of Sep. 30, 2021.
[cited by applicant]
Vyavahare et al., “Analysis of Structural Rearrangements of Poly(lactic acid) in the Presence of Water”, The Journal of Physical Chemistry B, vol. 118, No. 15, pp. 4185-4193 (2014).
[cited by applicant]
Yu et al., “Nanotechnology for Protein Delivery: Overview and Perspectives”, J. Control. Release, vol. 240, pp. 24-37 (2016).
[cited by applicant]
Zhang et al., “Development of Nanoparticles for Antimicrobial Drug Delivery” Current Medicinal Chemistry, vol. 17, No. 6, pp. 585-594 (2010).
[cited by applicant]
Tang et al., “An innovative method for preparation of hydrophobic ion-pairing colistin entrapped poly(lactic acid) nanoparticles: Loading and release mechanism study”, European J. Pharmaceutical Sciences, vol. 102, pp. …
[cited by applicant]
Anton et al., “Aqueous-Core Lipid Nanocapsules for Encapsulating Fragile Hydrophilic and/or Lipophilic Molecules,” Langmuir, vol. 25, No. 19, pp. 11413-11419 (2009).
[cited by applicant]
Bilati et al., “Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles”, European J. Pharmaceutical Sciences, vol. 24, pp. 67-75 (2005).
[cited by applicant]
Arshady, “Preparation of biodegradable microspheres and microcapsules: 2. Polyactides and related polyesters”, Journal of Controlled Release, vol. 17, pp. 1-22, (1991).
[cited by applicant]
Bilati et al., “Nanoprecipitation Versus Emulsion-based Techniques for the Encapsulation of Proteins Into Biodegradable Nanoparticles and Process-related Stability Issues”, AAPS PharmSciTech, vol. 6, No. 4, Article 74, …
[cited by applicant]
Bontha et al., “Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs”, Journal of Controlled Release, vol. 114, pp. 163-174 (2006).
[cited by applicant]
Bronich et al., “Polymer Micelle with Cross-Linked lonic Core”, J. Am. Chem Soc., vol. 127, pp. 8236-8237 (2005).
[cited by applicant]
Bronich et al., “Soluble Complexes from Poly(ethylene oxide)-block-polymethacrylate Anions and N-Alkylpyridinium Cations”, Macromolecules, vol. 30, pp. 3519-3525 (1997).
[cited by applicant]
D'Addio et al., “Controlling drug nanoparticle formation by rapid precipitation”, Advanced Drug Delivery Reviews, vol. 63, pp. 417-426 (2011).
[cited by applicant]
Extended European Search Report (EESR) issued Jan. 8, 2018 in European Application No. 15811879.4.
[cited by applicant]
Gao et al., “Core Cross-Linked Reverse Micelles from Star-Shaped Polymers,” Chemistry of Materials, vol. 20, pp. 3063-3067 (2008).
[cited by applicant]
Holland et al., “Polymers for Biodegradable Medical Devices, 1. The Potential of Polyesters As Controlled by Macromolecular Release Systems”, Journal of Controlled Release, vol. 4, pp. 155-180 (1986).
[cited by applicant]
Deng et al., “Janus Nanoparticles of Block Copolymers by Emulsion Solvent Evaporation Induced Assembly,” Macromolecules, vol. 49, pp. 1362-1368 (2016).
[cited by applicant]
Foerster et al., “Amphiphilic Block Copolymers in Structure-Controlled Nanomaterial Hybrids”, Advanced Materials, vol. 10, No. 3, pp. 195-217 (1998).
[cited by applicant]
Google Scholar NPL search string—downloaded Apr. 29, 2020, 1 page.
[cited by applicant]
Groeschel et al., “Guided hierarchical co-assembly of soft patchy nanoparticles”, Nature, vol. 503, pp. 247-251 (5 pages & 11 pages Methods, Extended Data Figures 1-9, & Extended Data Table 1) (Nov. 14, 2013).
[cited by applicant]
Guo et al., “Binding of dihydromyricetin and its metal ion complexes with bovine serum albumin”, Biotechnology & Biotechnological Equipment, vol. 28, No. 2, pp. 333-341 (2014).
[cited by applicant]
Guo et al., “Synthesis of dihydromyricetin-manganese (II) complex and interaction with DNA”, J. Molecular Structure, vol. 1027, pp. 64-69 (2012).
[cited by applicant]
International Search Report and Written Opinion mailed Dec. 6, 2018 in International Application No. PCT/US2018/050714.
[cited by applicant]
International Search Report and Written Opinion mailed Jan. 15, 2019 in International Application No. PCT/US2018/049580.
[cited by applicant]
International Search Report and Written Opinion mailed Feb. 22, 2019 in International Application No. PCT/US2018/058869.
[cited by applicant]
International Search Report and Written Opinion mailed Nov. 22, 2019 in International Application No. PCT/US2019/042574.
[cited by applicant]
Int'l Search Report and Written Opinion mailed Jul. 16, 2015 in Int'l Application No. PCT/US2015/017590.
[cited by applicant]
Int'l Search Report and Written Opinion mailed Sep. 18, 2015 in Int'l Application PCT/US2015/036060.
[cited by applicant]
Int'l Search Report and Written Opinion mailed Mar. 23, 2017 in Int'l Application No. PCT/US2016/068145.
[cited by applicant]
Int'l Search Report and Written Opinion mailed Jan. 26, 2018 in Int'l Application No. PCT/US2017/054779.
[cited by applicant]
IQQueryQuickExport search results—202004301516 (IP.com NPL search results)—downloaded Apr. 30, 2020, 4 pages.
[cited by applicant]
IQQueryQuickExport search results—202004301547 (IP.com NPL search results)—downloaded Apr. 30, 2020, 2 pages.
[cited by applicant]
IQQueryQuickExport search results—202004301605 (IP.com NPL search results)—downloaded Apr. 30, 2020, 5 pages.
[cited by applicant]
IQQueryQuickExport search results—202004301643 (IP.com NPL search results)—downloaded Apr. 30, 2020, 5 pages.
[cited by applicant]
IQQueryQuickExport search results—202004301659 (IP.com NPL search results)—downloaded Apr. 30, 2020, 5 pages.
[cited by applicant]
IQQueryQuickExport search results—202004301700 (IP.com NPL search results)—downloaded Apr. 30, 2020, 2 pages.
[cited by applicant]
Jang et al., “Bicontinuous Block Copolymer Morphologies Produced by Interfacially Active, Thermally Stable Nanoparticles”, Macromols., vol. 44, pp. 9366-9373 (2011).
[cited by applicant]
Jang et al., “Synthesis of thermally stable Au-core/Pt-shell nanoparticles and their segregation behavior in diblock copolymer mixtures”, Soft Matter, vol. 7, pp. 6255-6263 (2011), doi: 10.1039/clsm05223c.
[cited by applicant]
Jeon et al., “Cooperative Assembly of Block Copolymers with Deformable Interfaces: Toward Nanostructured Particles”, Advanced Materials, vol. 20, pp. 4103-4108 (2008), doi: 10.1002/adma.200801377.
[cited by applicant]
Johnson et al., “Nanoprecipitation of organic actives using mixing and block copolymer stabilization”, Abstracts of Papers of the American Chemical Society, No. 186 (Abstract) (Sep. 2003).
[cited by applicant]
Johnson et al., “Characterization and Suitability of Therapeutic Antibody Dense Phases for Subcutaneous Delivery”, Molecular Pharmaceutics, vol. 10, pp. 3582-3591 (2013).
[cited by applicant]
Johnson et al., “Chemical Processing and Micromixing in Confined Impinging Jets”, AlChE Journal, vol. 49, No. 9, pp. 2264-2282 (2003).
[cited by applicant]
Johnston et al., “Concentrated Dispersions of Equilibrium Protein Nanoclusters That Reversibly Dissociate into Active Monomers”, ACS Nano, vol. 6, No. 2, pp. 1357-1369 (2012).
[cited by applicant]
Kakizawa et al., “Controlled release of protein drugs from newly developed amphiphilic polymer-based microparticles composed of nanoparticles”, Journal of Controlled Release, vol. 142, pp. 8-13 (2010).
[cited by applicant]
Kang et al., “Pore Closing and Opening in Biodegradable Polymers and Their Effect on the Controlled Release of Proteins”, Mol. Pharmaceutics, vol. 4, No. 1, pp. 104-118 (2007).
[cited by applicant]
Kim et al., “Critical effect of freezing/freeze-drying on sustained release of FITC-dextran encapsulated within PLGA microspheres”, Int'l J. Pharmaceutics, vol. 271, pp. 207-214 (2004).
[cited by applicant]
Kumar et al., “Amphiphilic Janus particles at fluid interfaces”, Soft Matter, vol. 9, pp. 6604-6617 (2013).
[cited by applicant]
Lavasanifar et al., “Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery”, Advanced Drug Delivery Reviews, vol. 54, pp. 169-190 (2002).
[cited by applicant]
Liu et al., “CFD Predictions for Chemical Processing in a Confined Impinging-Jets Reactor”, AlChE Journal, vol. 52, No. 2, pp. 731-744 (Feb. 2006).
[cited by applicant]
Liu et al., “Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation”, Chemical Engineering Science, vol. 63, pp. 2829-2842 (2008).
[cited by applicant]
Mitragotri et al. “Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies”, Nat. Rev. Drug Discov., vol. 13, No. 9, pp. 655-672 (Sep. 2014).
[cited by applicant]
Okuyama et al., “Preparation of functional nanostructured particles by spray drying”, Advanced Powder Technol., vol. 17, No. 6, pp. 587-611 (2006).
[cited by applicant]
O'Reilly et al., “Cross-linked block copolymer micelles: functional nanostructures of great potential and versatility”, Chemical Society Reviews, vol. 35, pp. 1068-1083 (2006).
[cited by applicant]
Liu et al., “Janus Colloids Formed by Biphasic Grafting at a Pickering Emulsion Interface”, Angew. Chem., vol. 120, pp. 4037-4039 (2008).
[cited by applicant]
Mai et al., “Controlled Incorporation of Particles into the Central Portion of Vesicle Walls”, J. Am. Chem. Soc., vol. 132, pp. 10078-10084 (2010).
[cited by applicant]
Aggarwal et al., “What's fueling the biotech engine—2012 to 2013”, Nat. Biotechnol., vol. 32, No. 1, pp. 32-39, Jan. 2014.
[cited by applicant]
Ansell et al., “Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates,” Journal of Medicinal Chemistry, vol. 51, No. 11, pp. 3288-3296 (2008).
[cited by applicant]
Antonietti et al, “Polyelectrolyte-Surfactant Complexes: A New Type of Solid, Mesomorphous Material,” Macromolecules, vol. 27, No. 21, pp. 6007-6011 (1994).
[cited by applicant]
Antonov et al., “Entering and exiting the protein?polyelectrolyte coacervate phase via nonmonotonic salt dependence of critical conditions,” Biomacromolecules, vol. 11, No. 1, pp. 51-59 (2010).
[cited by applicant]
Bruno et al., Basics and recent advances in peptide and protein drug delivery, Therapeutic Delivery, vol. 4, No. 11, pp. 1443-1467 (2013).
[cited by applicant]
Crater et al., “Barrier Properties of Gastrointestinal Mucus to Nanoparticle Transport,” Macromolecular Bioscience, vol. 10, No. 12, pp. 1473-1483 (2010).
[cited by applicant]
Cu et al., “Drug delivery: Stealth particles give mucus the slip,” Nature Materials, vol. 8, No. 1, pp. 11-13 (2009).
[cited by applicant]
Davies et al., “Recent advances in the management of cystic fibrosis,” Archives of Disease in Childhood, vol. 99, No. 11, pp. 1033-1036 (2014).
[cited by applicant]
Ensign et al., “Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers,” Advanced Drug Delivery Reviews, vol. 64, No. 6, pp. 557-570 (2012).
[cited by applicant]
Galindo-Rodriguez et al., “Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 22, No. 5, pp. 419-464 (2…
[cited by applicant]
Gaudana et al., “Design and evaluation of a novel nanoparticulate-based formulation encapsulating a HIP complex of lysozyme,” Pharmaceutical Development and Technology, vol. 18, No. 3, pp. 752-759 (2013).
[cited by applicant]
Gindy et al., “Mechanism of macromolecular structure evolution in self-assembled lipid nanoparticles for siRNA delivery,” Langmuir, vol. 30, No. 16, pp. 4613-4622 (2014).
[cited by applicant]
Gregory et al., “Adsorption and flocculation by polymers and polymer mixtures”, Advances in Colloid and Interface Science, vol. 169, No. 1, pp. 1-12 (2011).
[cited by applicant]
Horigome, et al., “Long-Time Relaxation of Suspensions Flocculated by Associating Polymers”, Langmuir, vol. 18, No. 6, pp. 1968-1973 (2002).
[cited by applicant]
Høiby, N., “Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis” BMC Medicine, vol. 9, No. 32, pp. 1-7 (2011).
[cited by applicant]
Ilton et al., “Direct Measurement of the Critical Pore Size in a Model Membrane”, Physical Review Letters, vol. 117, Issue 25, pp. 257801-1-257801-5 (Dec. 2016).
[cited by applicant]
Immordino et al., “Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential,” International Journal of Nanomedicine, vol. 1, No. 3, pp. 297-315 (2006).
[cited by applicant]
International Preliminary Report on Patentability issued Mar. 26, 2020 in International Application No. PCT/US2018/050714.
[cited by applicant]
International Search Report and Written Opinion issued Feb. 22, 2019 in International Application No. PCT/US2018/058869.
[cited by applicant]
International Search Report and Written Opinion issued Dec. 6, 2018 in International Application No. PCT/US2018/050714.
[cited by applicant]
Jain et al., “Peptide and Protein Delivery Using New Drug Delivery Systems,” Crit. Rev. Ther. Drug Carrier Syst., vol. 30, No. 4, pp. 293-329 (2013).
[cited by applicant]
Johnson et al., “Flash NanoPrecipitation of Organic Actives and Block Copolymers using a Confined Impinging Jets Mixer,” Australian Journal of Chemistry, vol. 56, No. 10, pp. 1021-1024 (2003).
[cited by applicant]
Khanvilkar et al., “Drug transfer through mucus,” Advanced Drug Delivery Reviews, vol. 48, Nos. 2-3, pp. 173-193 (2001).
[cited by applicant]
Kovalainen et al., “Novel Delivery Systems for Improving the Clinical Use of Peptides”, Pharmacol. Rev., vol. 67, No. 3, pp. 541-561 (Jul. 2015).
[cited by applicant]
Lai et al., “Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues,” Advanced Drug Delivery Reviews, vol. 61, No. 2, pp. 158-171 (2009).
[cited by applicant]
Lai et al., “Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus,” Proceedings of the National Academy of Sciences, vol. 104, No. 5, pp. 1482-1487 (2007).
[cited by applicant]
Langer, “Drug delivery and targeting,” Nature, vol. 392, No. 6679, pp. 5-10 (1998).
[cited by applicant]
Li et al., “Pharmacokinetics and Biodistribution of Nanoparticles,” Molecular Pharmaceutics, vol. 5, No. 4, pp. 496-504 (2008).
[cited by applicant]
Liu et al., “Ostwald Ripening of beta-Carotene Nanoparticles,” Phys. Rev. Lett., vol. 98, No. 3, pp. 036102-1-036102-4 (2007).
[cited by applicant]
Livraghi et al., “Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance,” Toxicologic Pathology, vol. 35, No. 1, pp. 116-129 (2007).
[cited by applicant]
Lu et al., “Hydrophobic Ion Pairing of Peptide Antibiotics for Processing into Controlled Release Nanocarrier Formulations”, Molecular Pharmaceutics, vol. 15, No. 1, pp. 216-225 (2018).
[cited by applicant]
Luo et al., “Synthetic DNA delivery systems,” Nature Biotechnology, vol. 18, No. 1, pp. 33-37 (2000).
[cited by applicant]
Marcus et al., “Ion Pairing,” Chemical Reviews, vol. 106, No. 11, pp. 4585-4621 (2006).
[cited by applicant]
Markwalter et al., “Inverse Flash NanoPrecipitation for Biologics Encapsulation: Understanding Process Losses via an Extraction Protocol”, Control of Amphiphile Self-Assembling at the Molecular Level: Supra-Molecular As…
[cited by applicant]
Matschiner et al., “Optimization of topical erythromycin formulations by ion pairing,” Skin Pharmacology: The Official Journal of the Skin Pharmacology Society, vol. 8, No. 6, pp. 319-325 (1995).
[cited by applicant]
Meyer et al. “Hydrophobic lon Pairing: Altering the Solubility Properties of Biomolecules,” Pharmaceutical Research, vol. 15, No. 2, pp. 188-193 (1998).
[cited by applicant]
Muehle et al., “Stability of Particle Aggregates in Flocculation with Polymers: Stabilität von Teilchenaggregaten bei der Flockung mit Polymeren”, Chemical Engineering and Processing: Process Intensification, vol. 29, N…
[cited by applicant]
Mueller et al., “Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, No. 1, pp. 161-177 (2000).
[cited by applicant]
Muheem et al., “A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives,” Saudi Pharmaceutical Journal, vol. 24, No. 4, pp. 413-428 (2016).
[cited by applicant]
Notice of Allowance mailed Apr. 12, 2022 in U.S. Appl. No. 16/253,850.
[cited by applicant]
Overbeek et al., “Phase separation in polyelectrolyte solutions. Theory of complex coacervation,” Journal of Cellular Physiology, vol. 49, No. S1, pp. 7-26 (1957).
[cited by applicant]
Owens et al., “Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles,” International Journal of Pharmaceutics, vol. 307, No. 1, pp. 93-102 (2006).
[cited by applicant]
Pagels et al., “Inverse Flash NanoPrecipitation for Biologics Encapsulation: Nanoparticle Formation and Ionic Stabilization in Organic Solvents”, ACS Symp. Ser. 1271, pp. 249-274 (2017).
[cited by applicant]
Patel et al., “A novel approach for antibody nanocarriers development through hydrophobic ion-pairing complexation” Journal of Microencapsulation, vol. 31, No. 6, pp. 542-550 (2014).
[cited by applicant]
Pattni et al., “New Developments in Liposomal Drug Delivery,” Chemical Reviews, vol. 115, No. 19, pp. 10938-10966 (2015).
[cited by applicant]
Pham et al., “Micellar Solutions of Associative Triblock Copolymers: Entropic Attraction and Gas-Liquid Transition”, Macromolecules, vol. 32, No. 9, pp. 2996-3005 (1999).
[cited by applicant]
Pinkerton et al., “Formation of stable nanocarriers by in situ ion pairing during block-copolymer directed rapid precipitation,” Molecular Pharmaceutics, vol. 10, No. 1, pp. 319-328 (2013).
[cited by applicant]
Pustulka, K.M et al., Flash Nanoprecipitation: Particle Structure and Stability, Mol. Pharmaceutics, 10, 4367-4377 (2013).
[cited by applicant]
Reinhold et al., “Self-healing Microencapsulation of Biomacromolecules without Organic Solvents”, Angew. Chem. Int. Ed. Engl., vol. 51, No. 43, pp. 10800-10803 (2012).
[cited by applicant]
Reinhold et al., “Self-Healing Microencapsulation of Biomacromolecules without Organic Solvents”, Angewandte Chemie, vol. 124, Issue 43, pp. 10958-10961 (2012).
[cited by applicant]
Pagels et al., “Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics,” Journal of Controlled Release, vol. 219, pp. 519-535 (2015).
[cited by applicant]
Patil et al., “Retention of trypsin activity in spermine alginate microcapsules”, Journal of Microencapsulation, vol. 14, No. 4, pp. 469-474 (1997).
[cited by applicant]
Peters et al., “Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically According to the Tufts Center for the Study of Drug Development”, Nov. 14, 2013, https://www.biospace.com/...a-clinical-pipelines…
[cited by applicant]
Pitt, “The controlled parenteral delivery of polypeptides and proteins”, International Journal of Pharmaceutics, vol. 59, pp. 173-196 (1990).
[cited by applicant]
Prud'Homme et al., “Process for Encapsulating Soluble Biologics Therapeutics, and Imaging Agents”, U.S. Appl. No. 16/064,935, filed Jun. 21, 2018.
[cited by applicant]
Pustulka et al., “Flash Nanoprecipitation: Particle Structure and Stability,” Molecular Pharmaceutics, vol. 10, pp. 4367-4377 (2013).
[cited by applicant]
Riess et al.,“Emulsifying Properties of Block Copolymers. Oil-Water Emulsions and Microemulsions”, Polym. Eng. Sci., vol. 17, No. 8, pp. 634-638 (1977).
[cited by applicant]
Saad et al., “Principles of nanoparticle formation by Flash Nanoprecipitation”, Nano Today, vol. 11, No. 2, pp. 212-227 (2016), http://dx.doi.org/10.1016/j.nantod.2016.04.006.
[cited by applicant]
Sahoo et al., “Characterization of Porous PLGA/PLA Microparticles as a Scaffold for Three Dimensional Growth of Breast Cancer Cells”, Biomacromolecules, vol. 6, pp. 1132-1139 (2005).
[cited by applicant]
Sato et al., “Therapeutic peptides: technological advances driving peptides into development”, Current Opinion in Biotechnology, vol. 17, pp. 638-642 (2006).
[cited by applicant]
Solaro et al., “Targeted Delivery of Protein Drugs by Nanocarriers”, Materials, vol. 3, No. 3, pp. 1928-1980 (2010).
[cited by applicant]
Sosa et al., “Soft Multifaced and Patchy Colloids by Constrained Volume Self-Assembly”, Macromolecules, vol. 49, pp. 3580-3585 (2016).
[cited by applicant]
Steichen et al., “A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics”, European J. Pharmaceutical Sciences, vol. 48, pp. 416-427 (2013).
[cited by applicant]
U.S. Patent & Trademark Office (USPTO) Office Action dated May 12, 2021 for U.S. Appl. No. 16/810,710.
[cited by applicant]
U.S. Appl. No. 15/321,588 Notice of Allowance of Oct. 24, 2018.
[cited by applicant]
U.S. Appl. No. 15/321,588 Office Action of Apr. 10, 2018.
[cited by applicant]
U.S. Appl. No. 15/321,588 Restriction Requirement of Dec. 1, 2017.
[cited by applicant]
U.S. Appl. No. 15/321,588 Summary of Examiner Interview of Oct. 9, 2018.
[cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowance of Aug. 2, 2021.
[cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowance of Jun. 21, 2021.
[cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowance of Oct. 21, 2020.
[cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowance of Apr. 28, 2021.
[cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowance of May 6, 2020.
[cited by applicant]
U.S. Appl. No. 16/064,935 Requirement for Restriction/Election of Jan. 13, 2020.
[cited by applicant]
Wang et al., “Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres”, J. Controlled Release, vol. 82, pp. 289-307 (2002).
[cited by applicant]
Xu et al., “Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus”, Journal of Controlled Release, vol. 170, pp. 279-286 (2013).
[cited by applicant]
Zandonella, “Bob Prud'homme—Flash NanoPrecipitation” http://research.princeton.edu/news/features/a/index.xml?id=6234, accessed Mar. 9, 2018, originally published Dec. 9, 2011, 2 printed pages.
[cited by applicant]
Zhang et al., “Amphiphilic cylindrical brushes with poly(acrylic acid) core and poly(n-butyl acrylate) shell and narrow length distribution”, Polymer, vol. 44, pp. 1449-1458 (2003).
[cited by applicant]
Zhu et al., “Preparation and characterization of hCG-loaded polylactide or poly(lactide-co-glycolide) microspheres using a modified water-in-oil-in-water (w/o/w) emulsion solvent evaporation technique,” J. Microencapsul…
[cited by applicant]
U.S. Appl. No. 17/260,640 Office Action dated Oct. 30, 2023.
[cited by applicant]
U.S. Appl. No. 17/260,640 Notice of Allowance & Notice of Allowability dated Mar. 13, 2024.
[cited by applicant]
U.S. Appl. No. 17/260,640 Notice of Allowance & Notice of Allowability dated Aug. 16, 2024.
[cited by applicant]
U.S. Appl. No. 17/260,640 Corrected Notice of Allowability dated Nov. 20, 2024.
[cited by applicant]
U.S. Appl. No. 17/260,640 Interview Summary dated Mar. 13, 2024 for Examiner Interview of Feb. 29, 2024.
[cited by applicant]
U.S. Appl. No. 17/260,640 Interview Summary dated Apr. 12, 2024 for Examiner Interview of Feb. 29, 2024.
[cited by applicant]
U.S. Appl. No. 17/260,640 Interview Summary dated Jul. 9, 2024 for Examiner Interview of Jun. 13, 2024.
[cited by applicant]
U.S. Appl. No. 16/761,140 Notice of Allowance & Notice of Allowability dated Nov. 14, 2024.
[cited by applicant]
U.S. Appl. No. 16/761,140 Interview Summary dated Nov. 14, 2024 for Examiner Interview of Oct. 30, 2024.
[cited by applicant]
U.S. Appl. No. 16/517,510 Notice of Allowance & Notice of Allowability dated Apr. 19, 2023.
[cited by applicant]
U.S. Appl. No. 16/761,140 Office Action dated Feb. 14, 2024.
[cited by applicant]
U.S. Appl. No. 16/761,140 Office Action dated Jun. 5, 2023.
[cited by applicant]
U.S. Appl. No. 16/816,241 Notice of Allowance & Notice of Allowability dated Mar. 7, 2023.
[cited by applicant]
U.S. Appl. No. 16/816,241 Notice of Allowance & Notice of Allowability dated Apr. 13, 2023.
[cited by applicant]
U.S. Appl. No. 16/810,710 Restriction/Election Requirement dated Jan. 6, 2021.
[cited by applicant]
U.S. Appl. No. 16/810,710 Office Action dated Mar. 30, 2022.
[cited by applicant]
U.S. Appl. No. 17/899,157 Restriction/Election Requirement dated Oct. 30, 2023.
[cited by applicant]
U.S. Appl. No. 17/899,157 Office Action dated Apr. 10, 2024.
[cited by applicant]
Hadinoto et al., “Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review”, European Journal of Pharmaceutics & Biopharmaceutics, vol. 85, No. 3, part A, pp. 427-443 (2013).
[cited by applicant]
International Patent Application PCT/US2020/031579 International Search Report and Written Opinion dated Aug. 3, 2020.
[cited by applicant]
International Patent Application PCT/US2020/037542 International Search Report and Written Opinion dated Sep. 11, 2020.
[cited by applicant]
International Patent Application PCT/US2020/048986 International Search Report and Written Opinion dated Feb. 16, 2021.
[cited by applicant]
Johnson et al., “Engineering the Direct Precipitation of Stabilized Organic and Block Copolymer Nonparticles as Unique Composites”, Abstracts of Papers of the American Chemical Society, No. 441 (Abstract) (Sep. 2003).
[cited by applicant]
Kauffman et al., “Materials for non-viral intracellular delivery of messenger RNA therapeutics”, J. Controlled Release, vol. 240, pp. 227-234 (2016).
[cited by applicant]
Savjani, K.T. et al., “Drug Solubility: Importance and Enhancement Techniques”, ISRN Pharmaceutics, vol. 2012, Article ID 195727, pp. 1-10 (2012).
[cited by applicant]
Sheela, D.L. et al., “Laurie acid induce cell death in colon cancer cells mediated by the epidermal growth factor receptor downregulation: An in silica and in vitro study”, Human & Experimental Toxicology, (Epub. Apr. 3…
[cited by applicant]
Babu, N.J. & Nangia, A, “Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals”, Crystal Growth & Design, vol. 11, pp. 2662-2679 (2011).
[cited by applicant]
Bailly, N. et al. “Poly(N-vinylpyrrolidone)-block-poly(vinyl acetate) as a Drug Delivery Vehicle for Hydrophobic Drugs”, Biomacromolecules, vol. 13, pp. 4109-4117 (2012).
[cited by applicant]
BASF, Luviscol VA Grades Technical Information, Jun. 2012, pp. 1-14.
[cited by applicant]
“The Complete Guide to Enteric Coating”, https://astenzymes.com/the-complete-guide-to-enteric-coating/, pp. 1-11, accessed Aug. 11, 2020.
[cited by applicant]
“Enteric Coating—The Enteric Coating Process”, https://www.xtend-life.com/pages/enteric-coating, pp. 1-6, accessed Aug. 12, 2020.
[cited by applicant]
Etchenausia, L. et al., “RAFT/MADIX emulsion copolymerization of vinyl acetate and N-vinylcaprolactam: towards waterborne physically crosslinked thermoresponsive particles”, Polymer Chemistry, DOI: 10.1039/C7PY00221A, p…
[cited by applicant]
Guo, Q. et al., “Biosynthesis of gold nanoparticles using a kind of flavanol: Dihydromyricetin”, Colloids & Surfaces A: Physicochem. & Engineering Aspects, vol. 441, pp. 127-132 (2014).
[cited by applicant]